Vivanta 24 mg+26 mg (Tablet)
Unit Price: ৳ 45.00 (1 x 10: ৳ 450.00)
Strip Price: ৳ 450.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Sacubitril valsartan |
| Company | Beximco pharmaceuticals ltd |
| Also available as |
Indications
- To reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class ll-IV) and reduced ejection fraction
- For the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older
- Administered in conjunction with other heart failure therapies, in place of an angiotensin-converting enzyme inhibitor (ACEi) or other ARB
Pharmacology
- Contains a neprilysin inhibitor, sacubitril, and an angiotensin receptor blocker, valsartan
- Inhibits neprilysin (NEP) via LBQ657 and blocks the angiotensin II type-1 (AT1) receptor via valsartan
- Effects attributed to increased levels of peptides degraded by neprilysin and the simultaneous inhibition of the effects of angiotensin II by valsartan
- Inhibits angiotensin II-dependent aldosterone release
Dosage & Administration
- Recommended starting dose for adult heart failure: 49/51 mg orally twice daily
- Double the dose after 2 to 4 weeks to the target maintenance dose of 97/103 mg twice daily
- Reduce the starting dose for specific patient conditions
- Refer to table for pediatric dosage
- Recommended dose titration for pediatric patients based on weight categories
Interaction
- Dual Blockade of the Renin-Angiotensin-Aldosterone System
- Potassium-sparing Diuretics
- NSAIDs
- Lithium
Contraindications
- Hypersensitivity to any component
- History of angioedema related to previous ACE inhibitor or ARB therapy
- Concomitant use of ACE inhibitors or aliskiren in patients with diabetes
Side Effects
- Angioedema
- Hypotension
- Impaired Renal Function
- Hyperkalemia
- Cough
- Dizziness
Pregnancy & Lactation
- Safety and effectiveness in pediatric patients under 1 year of age not established
- No relevant pharmacokinetic differences observed in elderly patients
- No dose adjustment required in patients with mild hepatic impairment
- Not recommended in patients with severe hepatic impairment
- No dose adjustment required in patients with mild to moderate renal impairment
- Starting dose recommendation for patients with severe renal impairment
Precautions & Warnings
- May cause angioedema
- Lowers blood pressure and may cause symptomatic hypotension
- Closely monitor serum creatinine
- Monitor serum potassium periodically
- Dosage reduction or interruption may be required
Use in Special Populations
- Safety and effectiveness not established in pediatric patients
- No relevant pharmacokinetic differences observed in elderly patients
- Starting dose recommendation for patients with severe renal impairment
- Starting dose recommendation for patients with moderate hepatic impairment
- Not recommended for use in patients with severe hepatic impairment
Overdose Effects
- Limited data available on human overdosage
- Hypotension likely result of overdosage
- Symptomatic treatment should be provided
- Unlikely to be removed by hemodialysis due to high protein binding
Storage Conditions
- Keep in a dry place and store below 30°C
- Protect from moisture
- Keep out of the reach of children